Federal Circuit Tarceva decision is good news for oncology patent owners
Appellate court overturns PTAB invalidation, citing uncertainties of R&D in the lucrative cancer space, as well as lack of data in prior art
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now